Kazia Therapeutics Ltd (KZIA) News

Damnnn now $11s... That's nearly a triple boys and girls

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)
SYDNEY, June 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced the publication of transformative preclinical research in the journal Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research that underscores the powerful potential of its lead asset, paxalisib, in reshaping the treatment landscape for triple-negative breast cancer (TNBC), one of the most aggressive and treatment-resistant cancer subtypes.


The preclinical program was conducted by Professor Sudha Rao at the renowned QIMR Berghofer Medical Research Institute, revealing how paxalisib can reprogram the tumor microenvironment and enhance immune response, showing substantial synergy with immune checkpoint inhibitors. The data provide strong scientific and translational rationale for continued development of paxalisib as part of immunotherapy-based regimens.

Key Findings

Dual targeting of PI3K and mTOR but not PI3K alone inhibits cancer cell proliferation and migration in vitro.
Paxalisib remodels the TNBC tumor microenvironment, increasing CD4+ and CD8+ T cell infiltration and activation
The combination of paxalisib with KEYTRUDA® (pembrolizumab) demonstrated synergistic antitumor activity in advanced breast cancer, resulting in robust tumor regression and prolonged survival in preclinical models
The data validate a mechanistic rationale for ongoing clinical exploration of paxalisib in combination with checkpoint inhibitors and PARP inhibitors
"This landmark study offers a mechanistic and translational foundation for our newly launched Phase 1b clinical trial of paxalisib in advanced breast cancer," said Dr. John Friend, CEO of Kazia. "It not only extends the therapeutic potential of paxalisib beyond brain cancers but also positions it at the forefront of innovative immunotherapy combinations in solid tumors."

The publication, "Combination of the PI3K/mTOR inhibitor paxalisib with immune checkpoint inhibitors enhances antitumor activity in preclinical models of triple-negative breast cancer," is available online at https://aacrjournals.org/mct/article/doi/10.1158/1535-7163.MCT-24-0693/762929/Depleting-the-action-of-EZH2-through-PI3K-mTOR.

Clinical Milestone
Kazia recently announced that the first patient has been dosed in the Phase 1b trial evaluating paxalisib in combination with checkpoint inhibitors and chemotherapy in advanced breast cancer, marking a critical step toward clinical translation of these findings.

For investor and media, please contact Alex Star, Managing Director LifeSci Advisors LLC

About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024 and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad rang

KZIA under $4

KZIA: effective April 17,2025 a one for 5 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

Don't be a wise ass...🥳

Are you sure about that?

KZIA...$1.55... 🥳...https://schrts.co/QpVScFSV...Looking for Triple Bottom Bounce...Open Gap filled from the $2.60 Range Spike...3 Million Range Float...

KZIA: For the same reasons that you RARELY see images of even one WOMAN on the Dow Jones trading FLOOR, NYSE, etc,!!! Do you??? Have you not seen those OBLIGATORY daily images on your computer of MEN up close standing, gesticulating, etc., on the FLOOR of the various EXCHANGES???? And that MALE CHAUVINISM applies to even greater magnitudes to anything about WOMEN'S health issues!! And that's why neither HILARY nor KAMALA ever got close to that WHITE HOUSE, bro!!! Sick & sad, but TRUE!! And lastly, if you still doubt the veracity of what I have just said, then toss some MONEY at KZIA right now, Homeboy!!!

Why would that be the case?

KZIA: Flip-out quick!! (Women's Cancer issues normally do NOT fly!!)

NICE!! You got a runner bro!🤩

$2.68 + 90% all out now in at $1.91'

KZIA............................https://stockcharts.com/h-sc/ui?s=KZIA&p=W&b=5&g=0&id=p86431144783

Flip back out $2.29

$1.91 ... SYDNEY, Jan. 30, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offers what is believed to be a unique approach to targeting this highly aggressive and treatment-resistant type of breast cancer.

What the heck is going on with this company? Anyone?

is the reversal here yet?

Thanks for the heads up!😆

Reverse split completed watch for a reversal then add some 

KZIA .36 to .50s + 50% . Aussie company little run

Who? lol

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Big Upward Move Coming. FDA Approval Probably

$1 break is close.

Buying is picking up

.70 close is a good possibility.

Grabbed a few more.

More charts... se replied to for long term chart.

Heading back below $0.50 the sellers of the $0.50 puts morons served on a half shell

credentials still work hadnt been here in a few years

interesting volume 3rd leg next week hmmmm

After Hours trading looking Good...

Should open above 1.50 at 9:30am...

Bought the Dip at 1.00 average...

GhosT

Is it too high to buy....Volume was good...Has seemed to Wane a bit...

Good Call Ghost...This thing ran from 20 to 160 in a couple days...wow...I remember seeing it at 30...

Closed my Position at 1.45 average...

On watch for now...

GhosT

TOP IN AGAIN

Thank you Tommyboy🥰

$KZIA
$KZIA Highlighted the break over the 200 day MA yesterday during trading..pointed out how much room it had to run..just over $1 now Premarket..In pure beast mode now.. let’s see if it can get through the residence between $1-$1.15.. pic.twitter.com/YHRJarumZR— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) July 11, 2024

If you can stomach the volatility then you will be just fine!

Yes indeed ! Have they applied for FDA

I feel you have to go with Xena's chart in the long term. The News yesterday was huge and moving forward if this passes phase 3 FDA approval a major pharmaceutical Company will buy it out!

Hi all. im new here. The explosion yesterday brought me to this stock. Am I late or has this got the potential to break over a dollar. thanks

Intriguing long term chart...



another chart:

algo trap

$KZIA +248% #DDAmanda Video Analysis - #1 Stock Scanner/Screener



Z

KZIA: My BAD!!! ("Finviz", below, says YOU are correct!!)
https://finviz.com/quote.ashx?t=KZIA&p=d
Google, below, mislead me:
https://www.google.com/search?q=kzia+stock+float&sca_esv=54722a0b5ffac30e&sca_upv=1&source=lnms&sa=X&ved=2ahUKEwjyta_75Z2HAxWIBe8CHd5GABEQ0pQJegQIBRAC&biw=1366&bih=657&dpr=1

The outstanding shares are only about 23,000,000:
https://www.otcmarkets.com/stock/KZIA/security

Nice strong A.H. close at .95 :)

After Hours trading looking good...

Should open above 1.00 at 9:30am...

Bought the Dip 0.58 average...

GhosT

KZIA: 243-million Float, & yet soared like that??? (O.K., so there goes the old "Small-Float" theory.)

KZIA........................................https://stockcharts.com/h-sc/ui?s=KZIA&p=W&b=5&g=0&id=p86431144783

yeah, mine wasn't top of cloud but .40 to .82 not bad i guess